Abstract
Recombinant human PDGF BB homodimer (rhPDGF-BB) is a potent chemotactic and mitogenic factor for cells crucial to musculoskeletal tissue repair, including mesenchymal stem cells (MSCs), osteogenic cells, and tenocytes. Furthermore, rhPDGF-BB promotes angiogenesis by upregulation of vascular endothelial growth factor (VEGF). These properties allow rhPDGF-BB to initiate the tissue repair and regeneration cascade, a mechanism of action that has been demonstrated through preclinical and clinical studies. The established mechanism of action and preclinical safety profile of rhPDGF-BB support clinical investigation of this molecule in diverse conditions that require osseous repair. Furthermore, the safety and efficacy profiles of rhPDGF-BB observed in the healing of chronic foot ulcers in diabetic patients along with previously reported preclinical data in orthopaedic models provide additional rationale to assess the application of rhPDGF-BB containing scaffolds in bone applications, including periodontal disease and end-stage ankle arthritis. Additional combinations of rhPDGF-BB with tissue-specific matrices are being studied in additional clinical musculoskeletal indications, such as rotator cuff repair involving tendon and bone integration. This paper reviews the clinical experience with rhPDGF-BB in bone repair.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
